Abstract
Cardiac arrest remains one of the most common causes of death in developed countries. Those who survive may have significant neurologic morbidity. In the current decade, therapeutic medical hypothermia (TMH) has emerged as the only treatment that unequivocally improves neurologic outcomes in post ventricular fibrillation / ventricular tachycardia induced cardiac arrest. The role of TMH in other forms of cardiac arrest continues to evolve. We present the current status of medical hypothermia, recent patents and recent advances of this evolving therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
